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Abstract 
The phenomenon of supercooperativity n platelet aggregation is manifested bythe occurence of clear-cut thresholds in dose-response relationships; 
in such cases the Hill coefficient has unusually high values. Approximation, by the Hill equation, ofthe relationship of the rate ofarachidonate-induced 
platelet aggregation to the concentrations f either the inducer or inhibitors such as substituted pyridyl isoxazoles ( ynthesized by us), indomethacin, 
and pinane thromboxane A2,demonstrated hat he Hill coefficients ranged from 30 to 100. 3-(3-Pyridyl)-5-phenylisoxazole, which exhibited maximal 
anti-aggregatory activity among the synthesized compounds, inhibited neither cyclooxygenase northromboxane synthase. The compounds affected 
the signal transduction pathway at/or posterior to the stage of thromboxane A2 reception. 
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I. Introduction 
Platelet aggregation is the most important defensive 
mechanism preventing the organism from blood loss 
upon vessel wall damage [1]. The platelets are bridged 
into aggregates by intercellular GP IIb/IIIa fibrinogen 
- GP IIb/IIIa bonds [2,3]. The exposure of GP IIb/IIIa, 
the platelet fibrinogen receptor, is the result of a series 
of successive biochemical processes, initiated by aggrega- 
tion inducers. Binding of the inducers (TxA2, ADP, sero- 
tonin, collagen, epinephrine, vasopressin, thrombin, 
platelet-activating factor) by their specific platelet recep- 
tors is an important element in this chain of events [4- 
10]. Such receptor- ligand interactions trigger off a vari- 
ety of G-protein-mediated ffects, e.g. activation of 
phospholipases (A 2 and/or C) and inhibition of adenylate 
cyclase [11-14]. Intracellular enzyme systems change the 
concentration of regulators and secondary messengers 
(inositol tris-phosphate, diacylglycerol, TxA2, cyclic 
AMP, Ca 2+, H ÷, etc.) [13,15-17] which constitute the 
signal transduction cascade. 
Hence, generation of aggregatory responses i the re- 
sult of transduction of chemical signals through multi- 
stage pathways. Although the exact number of stages is 
unknown, each stage is obviously characterized by a 
certain relationship between input and output signals. 
*Corresponding author. Fax: (7) (095) 9390997. 
Abbreviations: Tx, thromboxane; PTA2, pinane thromboxane A2,GP, 
glycoprotein; ADP, adenosine diphosphate; AMP, adenosine mono- 
phosphate; F, cell response; A, inducer; I, inhibitor; h, Hill coefficient; 
PRP, platelet-rich plasma; PPP, platelet-poor plasma; DMSO, dimeth- 
ylsulfoxide. 
Approximation of such relationships by the Hill equa- 
tion allowed us to analyze a generalized model of signal 
transduction [18,19]. The relationships of cell response 
(F) to inducer (A) or inhibitor (I) concentrations, which 
were obtained in the context of this model, can also be 
approximated by the Hill equation with a high degree of 
precision (Eqs. (1) and (2), respectively): 
([A]/KA) hA 
F/Fmax = 1 + ([A]/KA) hA (1) 
1 
F/Fmax - 1 + ([I]/K~) h~ (2) 
where K A is the EC50, Kl is the ICs0. 
It follows from the analysis [18] that, if the relationship 
between input and output signals at a given step of signal 
transduction is characterized by a very high value of the 
Hill coefficient (i.e. the step is supercooperative), theHill 
coefficient (hA) for the relationship of F to [A] (Eq. (1)) 
will also take an extremely high value (i.e. the relation- 
ship will be supercooperative). If an inhibitor I affects the 
signal transduction pathway at a stage preceding the 
supercooperative st p, the expression for hi will incorpo- 
rate the Hill coefficient value of the supercooperative 
step, and hi for the relationship of F to [I] (Eq. (2)) will 
also be very high (i.e. the relationship will be supercoop- 
erative). In this latter case the inhibitor should be termed 
'supercooperative inhibitor'. If an inhibitor affects the 
signal transduction pathway at or posterior to the 
supercooperative step, the Hill coefficient value of the 
supercooperative step will not enter Eq. (2), and the 
relationship of F to [I] in this case will be of ordinary 
cooperativity (the value of hl for such relationships i
usually comparable to unity). 
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2. Materials and methods 
2.1. Preparation of PRP 
Blood was drawn from cubital veins of normal volunteers into 1/10 
vol. of 3.8% trisodium citrate and centrifuged at 150 × g (room temper- 
ature) for 15 rain. 
Aggregation of platelets was measured as defined elsewere [19]. The 
aggregation rate (F) was calculated from the slope of each aggregation 
curve. In the results presented the aggregation rate is expressed as a 
fraction of the averaged maximal value obtained throughout a given 
experiment. 
2.2. Reagents 
ADP, indomethacin, hemin and arachidonic acid were purchased 
from Sigma (USA), PTA 2 from Calbiochem-Behring (USA), epineph- 
rine from Serva (Germany). 
Substituted pyridyl isoxazoles and isoxazolines were synthesized (to 
be published elsewere) by 1,3-cycloaddition f pyridyl nitrile oxides 
(generated in situ from pyridyI hydroxamoyl chlorides) to terminal 
alkynes and alkenes, respectively. Compounds (3a-c, 3g, 3i, 4a-c) were 
synthesized for the first time. The structures were assigned by tH NMR 
spectroscopy, mass spectrometry and element analysis. 
3. Results and discussion 
Our interest in substituted pyridyl isoxazoles as plate- 
let-affecting agents [20-21] relies on the assumption that 
bicyclic structures (including isoxazoline and isoxasolid- 
ine moieties) are largely complementary to the active 
sites of eicosanoid-binding receptors and enzymes [22- 
251. 
We synthesized and studied 3,5-substituted isoxazoles 
and isoxazolines, which contained pyridine fragments at 
position 3: 
3(a-i) 4(a-d) 
Where 3a (R = -CH2OH, R' = 2-Py), 3b (R = -CH2OH, 
R' = 3-Py), 3c (R = -CH2OH, R" = 4-Py), 3d (R = -C6H5, 
R' = 2-Py), 3e (R = -C6H5, R' = 3-Py), 3f (R = -C6H5, 
R' = 4-Py), 3g (R = -C(OH)(CH02, R' = 3-Py), 3h (R = 
-C1, R" = 4-Py), 3i (R = -CH2Br, R' = 2-Py), 4a (R = 
-CO2Et, R' = 3-Py), 4b (R = -CO2Et, R' = 4-Py), 4c 
(R = -(CH2)sCH3, R' = 3-Py), 4d (R = -OCOCH3, R" = 
3 -Py). 
The compounds ynthesized lacked proaggregatory 
activity up to 1 mM, but inhibited, within the range from 
1 to 1000 tiM, both arachidonate-induced platelet aggre- 
gation and the second phase of ADP-induced platelet 
aggregation (primary ADP-induced aggregation was not 
affected). 
Judging by IC50 values for arachidonate-induced 
platelet aggregation, pyridyl isoxazoles can be arranged 
in the following order of decreasing activity: 
3e> 3b>3f -> 3c> 3d> 3a. 
3-(3-Pyridyl)-5-phenylisoxazole (compound 3e) turned 
out to be the most active in this series. Fig. 1 shows the 
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Fig. 1. Relationship of the rate of arachidonate-induced human plate- 
let aggregation tothe concentration f 3-(3-pyridyl)-5-phenylisoxazole. 
Arachidonic acid, 500 #M. The theoretical curve is plotted using Eq. 
(2) (h~ = 30). 
relationship (obtained with PRP samples of 8 individu- 
als) of the rate of arachidonate-induced aggregation to 
the concentration f this compound, as plotted in dimen- 
sionless relative coordinates. This threshold-like rela- 
tionship can be described by Eq. (2) using a cooperativity 
coefficient (h~) equal to 30. 
In its turn, concentration-dependence of ara- 
chidonate-induced aggregation rate is described by Eq. 
(1) at hA = 30 (Fig. 2). Thus, in both cases the Hill 
coefficient considerably exceeds unity. Similar relation- 
ships were obtained for the second phases of ADP- or 
epinephrine-induced aggregation [19]. The inhibition of 
arachidonate-induced platelet aggregation by indometh- 
acin (a cyclooxygenase blocker) or PTA2 (a TxA2 recep- 
tor antagonist) is described by Eq. (2) at h~ = 100 (Fig. 
3). Here, again, the Hill coefficient substantially exceeds 
unity. 
As follows from the analysis [18], such supercoopera- 
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Fig. 2. Relationship of the rate of arachidonate-induced human plate- 
let aggregation to the concentration of the inducer. The theoretical 
curve is plotted using Eq. (1) (K A = 275 pM, h A = 30). 
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Fig. 3. Inhibition of arachidonate-induced human platelet aggregation 
by indomethacin orPTA 2. Arachidonic acid, 500/.tM. The theoretical 
curves are plotted using Eq. (2) (Indomethacin, K~= 1.62/IM, h~ = 100; 
PTA2, Ki = 1.0/.tM, hi = 100). 
tive relationships can arise from the existence of a super- 
cooperative step within the signal transduction pathway. 
In the case of  platelet aggregation, this step is located 
within the intracellular egion of  the pathway, since the 
extracellular stages (platelet collisions in the shear flow 
and aggregate formation) are characterized by ordinary 
cooperativity [26-28]. 
The supercooperative step is expected to be posterior 
to the stages of  arachidonate oxidation and TxA2 recep- 
tion. It is noteworthy that supercooperative effects could 
be observed with indomethacin-sensitive (arachidonate- 
dependent) second phases of  ADP-  and epinephrine-in- 
duced platelet aggregation, whereas the first phases of  
these responses (arachidonate-independent) were char- 
acterized by ordinary cooperativity [19]. Hence, the phe- 
nomenon of  supercooperativity may be associated with 
cyclooxygenase metabolism of arachidonate. 
To elucidate the mechanism whereby 3e inhibited 
platelet aggregation, we assessed the effects of  this com- 
pound on the activity of  the enzymes of the arachidonate 
cascade. In these experiments we used two enzyme prep- 
arations, cyclooxygenase from sheep vesicular glands 
and the microsomal fraction of  human platelets that con- 
tained both cyclooxygenase and Tx synthase. We were 
able to demonstrate that the tested compound inhibited 
neither cyclooxygenase, nor Tx synthase (up to 1,000 
/IM; data not shown). 
Hence, the substituted pyridyl isoxazoles synthesized 
by us are supercooperative inhibitors of platelet aggrega- 
tion and affect the signal transduction pathway at a stage 
preceding the supercooperative step. Compound 3e was 
similar in its kinetic characteristics to indomethacin and 
PTA2, but inhibited neither cyclooxygenase nor Tx syn- 
thase. In a series of  preliminary experiments we detected 
specific binding of  the tritium-labeled 3e to the platelet 
surface. Therefore, TxA2 receptors, which constitute the 
nearest possible target within the signal transduction 
pathway, might be affected by the isoxazole-containing 
compounds under study. 
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